Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Silexion Therapeutics Corp. has completed its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. SIL-204 is a next-generation siRNA candidate designed to target a broad range of ...
P/E ratio (year end quote, basic EPS) 253.37 259.61 - - P/E ratio (year end quote, diluted EPS) 253.37 259.61 - - Silexion Therapeutics Dividend Calendar Silexion Therapeutics Calendar Indices ...
Jushi Holdings Inc. ("Jushi” or the "Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis ...
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? These 10 mid-cap stocks performed well last week. Are they in ...
After hours: 7:59:02 p.m. EST ...
After hours: February 26 at 4:05:04 PM EST Loading Chart for MDCX ...
After hours: February 18 at 6:56:12 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results